Medical Condition News

RSS

New mouse model confirms mutation of beta-synuclein protein promotes neurodegeneration

A team of scientists from Japan and the University of California, San Diego School of Medicine have created a new mouse model that confirms that mutations of a protein called beta-synuclein promote neurodegeneration. The discovery creates a potential new target for developing treatments of diseases like Parkinson's and Alzheimer's.

3 Nov 2010

Roux-en-Y gastric bypass surgery effective for morbid obesity

Gastric bypass surgery decreases the preference for sweet-tasting substances in obese rats, a study finding that could help in developing safer treatments for the morbidly obese, according to Penn State College of Medicine researchers.

3 Nov 2010

Researchers discover FoxO1 protein interacts with macrophages to promote inflammatory response

Researchers at the University of California, San Diego School of Medicine have discovered that a multi-tasking protein called FoxO1 has another important but previously unknown function: It directly interacts with macrophages, promoting an inflammatory response that can lead to insulin resistance and diabetes. Contrarily, it also generates a negative feedback loop that can limit damage from excessive inflammation.

3 Nov 2010

Quanterix granted $733,437 under QTDP program for Single Molecule Array platform

Quanterix Corporation, a single molecule technology company focused on developing a next generation diagnostics platform, announced today that it was awarded a total of $733,437 in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP program recognized Quanterix's Single Molecule Array (SiMoA™) platform as a promising advance that will improve diagnosis and treatment of disease while reducing healthcare costs.

3 Nov 2010

Drinking beet juice increases blood flow to the brain

Researchers for the first time have shown that drinking beet juice can increase blood flow to the brain in older adults - a finding that could hold great potential for combating the progression of dementia.

3 Nov 2010

Enzon receives $1.2 million in funding under IRS Qualifying Therapeutic Discovery Project program

Enzon Pharmaceuticals, Inc. today announced that it has been awarded $1.2 million in funding under the IRS Qualifying Therapeutic Discovery Project (QTDP) program, which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.

3 Nov 2010

ImmunoGen to present clinical data of lead compounds at EORTC-NCI-AACR Symposium

ImmunoGen, Inc. a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that several ImmunoGen poster presentations will be made at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held in Berlin, Germany, November 16-19, 2010.

3 Nov 2010

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Hyperion Therapeutics, Inc. today announced that the Company's phase III pivotal study of glycerol phenylbutyrate (HPN-100), an investigational drug for the treatment of urea cycle disorders (UCDs), met its primary endpoint. The non-inferiority study, conducted under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA) in June 2009, evaluated the ammonia control of glycerol phenylbutyrate as compared to sodium phenylbutyrate (BUPHENYL®).

3 Nov 2010

Somaxon awarded $245,000 grant for Silenor under QTDP program

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to Silenor® (doxepin) under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.

3 Nov 2010

JenaValve commences CE-Mark study for transapical TAVI system

JenaValve™ Technology, Inc., a medical device company specialized in developing transcatheter valve replacement products, announced today the start of its multicenter CE-mark study. The first two implantations of its transapical TAVI system were performed by Dr. med. Hendrik Treede at the Universitäres Herzzentrum Hamburg.

3 Nov 2010

Staff member of U.S. preventive services task force quits over cancelled meeting

A member of the support staff for the United States Preventive Services Task Force has quit over the cancellation of a meeting scheduled for today and tomorrow at which the task force was due to vote on the controversial issue of prostate-cancer screening.

3 Nov 2010

BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer

Tikcro Technologies Ltd. today announced that BioCancell reported results from a Phase I/IIa clinical trial to establish the safety, optimal dose and preliminary efficacy of BioCancell's lead drug-candidate, BC-819, as a treatment for pancreatic cancer.

3 Nov 2010

Study demonstrates widespread internal exposure of humans to cosmetic UV filters

An investigation conducted in the context of the Swiss National Research Programme (NRP50), Endocrine Disrupters: Relevance to Humans, Animals and Ecosystems, demonstrates for the first time that internal exposure of humans to cosmetic UV filters is widespread.

3 Nov 2010

Brain Research Foundation presents Frederic A. Gibbs Discovery Award to Abbott

The Brain Research Foundation presented the Frederic A. Gibbs Discovery Award to Abbott, a global, broad-based health care company, for its dedication to advancing neuroscience through education, research and philanthropy.

3 Nov 2010

Illumina, Expression Analysis support Cancer GWAS and Data Analysis Grant program

Expression Analysis today announced that it and Illumina, Inc. are jointly funding a Cancer GWAS (Genome-Wide Association Study) and Data Analysis Grant program to support cutting-edge projects that show promise in identifying genetic elements important to cancer research and treatment.

From Illumina, Inc. 3 Nov 2010

FDA grants Cadence marketing approval for OFIRMEV injection in management of pain and fever

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for OFIRMEV™ (acetaminophen) injection, the first and only intravenous (IV) formulation of acetaminophen to be approved in the United States. OFIRMEV is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.

3 Nov 2010

Study finds DHA supplementation does not reduce risk of AD

Patients with mild to moderate Alzheimer's disease (AD) who received supplementation with the omega-3 fatty acid docosahexaenoic acid (DHA), believed to possibly reduce the risk of AD, did not experience a reduction in the rate of cognitive and functional decline, compared to patients who received placebo, according to a study in the November 3 issue of JAMA, a theme issue on aging.

3 Nov 2010

Atritech commences enrollment in WATCHMAN Left Atrial Appendage Closure Device study in AF patients

Atritech, Inc. today announced initial enrollment into its confirmatory study, PREVAIL, comparing the WATCHMAN® Left Atrial Appendage Closure Device to long term warfarin therapy in patients with atrial fibrillation. Doctors at Central Baptist Hospital in Lexington, Kentucky enrolled the first patient.

3 Nov 2010

Bristol-Myers extends time to review BLA for ipilimumab in melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has determined that additional time is required to complete the review of the biologics license application (BLA) for ipilimumab in pre-treated advanced melanoma, and has moved its decision date from December 25, 2010 to March 26, 2011.

3 Nov 2010

NeurogesX initiates NGX-1998 Phase 2 study in postherpetic neuralgia

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced dosing of the first patient in its Phase 2 clinical study of NGX-1998, a liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).

3 Nov 2010

Medical Condition News

New mouse model confirms mutation of beta-synuclein protein promotes neurodegeneration

Roux-en-Y gastric bypass surgery effective for morbid obesity

Researchers discover FoxO1 protein interacts with macrophages to promote inflammatory response

Quanterix granted $733,437 under QTDP program for Single Molecule Array platform

Drinking beet juice increases blood flow to the brain

Enzon receives $1.2 million in funding under IRS Qualifying Therapeutic Discovery Project program

ImmunoGen to present clinical data of lead compounds at EORTC-NCI-AACR Symposium

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Somaxon awarded $245,000 grant for Silenor under QTDP program

JenaValve commences CE-Mark study for transapical TAVI system

Staff member of U.S. preventive services task force quits over cancelled meeting

BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer

Study demonstrates widespread internal exposure of humans to cosmetic UV filters

Brain Research Foundation presents Frederic A. Gibbs Discovery Award to Abbott

Illumina, Expression Analysis support Cancer GWAS and Data Analysis Grant program

FDA grants Cadence marketing approval for OFIRMEV injection in management of pain and fever

Study finds DHA supplementation does not reduce risk of AD

Atritech commences enrollment in WATCHMAN Left Atrial Appendage Closure Device study in AF patients

Bristol-Myers extends time to review BLA for ipilimumab in melanoma

NeurogesX initiates NGX-1998 Phase 2 study in postherpetic neuralgia

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Latest News